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Abstract 
Anorexia is a problem of paramount importance in patients with advanced liver failure. Ghrelin has important actions 
on feeding and weight homeostasis. Concentrations of ghrelin are controversial in liver cirrhosis. Our aim was to 
study fasting ghrelin and their response to an oral glucose tolerance test (OGTT) in liver failure patients and normal 
subjects. Methods We included 16 patients with severe liver failure prior to liver transplantation. As a control group 
we included 10 age- and BMI-matched healthy subjects. After an overnight fast, 75 g of oral glucose were 
administered; glucose, insulin, and ghrelin were obtained at baseline and at times 30, 60, 90, and 120 min, 
respectively. Results Fasting ghrelin (median and range) were statistically significantly lower for patients compared 
to the controls, 527 (377–971) pg/ml vs. 643 (523–2163) pg/ml, P = 0.045, for patients and controls, respectively. 
The area under the curve for total ghrelin post-OGTT were lower in end-stage liver failure patients than in the control 
group, 58815 (44730–87420) pg/ml min vs. 76560 (56160–206385) pg/ml min, for patients and controls, 
respectively, P = 0.027. Conclusions Ghrelin levels are significantly decreased both fasting and post-OGTT in 
patients with liver failure candidates for transplantation. Decreased ghrelin levels could contribute to anorexia in 
patients with cirrhosis. 
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Introduction 
Malnutrition is common in patients with liver failure, with a reported prevalence as high as 80% 
depending on the severity of liver disease [1, 2]. The mechanisms of malnutrition in cirrhosis are not 
completely understood. Both poor dietary intake [2-4] and increased basal energy expenditure have been 
reported to contribute to a negative energy balance in patients with cirrhosis [1, 5, 6]. Anorexia is a 
problem of paramount importance in patients with advanced cirrhosis, contributing to malnutrition. The 
reasons for reduced food intake include hepatocellular failure to tense ascites, causing mechanical 
difficulties in feeding; poor palatability of a low-sodium diet; and, finally, increased brain tryptophan 
availability for serotonin synthesis [7]. In turn, malnutrition is a risk factor for the development of life-
threatening complications and increased mortality [8, 9], and any effort to promote regular feeding should 
be encouraged. Malnutrition is of paramount importance in patients with liver failure previous to liver 
transplantation. 
 
Ghrelin is a 28-amino-acid peptide, predominantly produced by the stomach, which has a unique 
structure with an n-octanoyl ester at its third serine residue, which is essential for its potent stimulatory 
activity on somatotroph secretion [10-12]. Apart from stimulating GH secretion, ghrelin has other 
endocrine and nonendocrine actions [13]. Different studies suggest the importance of ghrelin in feeding 
and weight homeostasis [14-16]. The infusion of ghrelin led to short-term increases in hunger in human 
subjects [17]. Although obese patients with Prader-Willi syndrome characterized by hyperphagia and 
obesity have elevated ghrelin levels [18], the concentrations of fasting ghrelin are increased in anorexia 
and cachexia but reduced in obesity [19-23] and plasma ghrelin levels are negatively correlated with body 
mass index, body fat mass and plasma leptin, insulin and glucose levels [22, 24, 25]. Insulin resistance 
has been postulated to play a role in determining the lower fasting plasma ghrelin in the obese [26]. 
Circulating plasma ghrelin increases before a meal and decreases following the consumption of nutrients 
and after an oral glucose tolerance test (OGTT) [27-29]. There are two major circulating forms of ghrelin: 
acyl and des-acyl ghrelin [13]. Acylated ghrelin has proved to be highly relevant in the development of 
metabolic disturbances, although total ghrelin has a well-established correlation with metabolic 
disturbances. In fact, most of the leading studies on the correlation between metabolic disturbances and 
ghrelin have focused on the estimation of total ghrelin [19-23, 27, 28], and there are concerns about the 
especificity of available acyl-ghrelin assays [30]. We concentrated on measuring total ghrelin, with the 
aim of comparing our data with the discrepant total ghrelin levels that have been found in hepatic failure 
patients in different studies [4, 31-35]. 
 
Experimental data exists which suggest that ghrelin could protect hepatic tissue. A ghrelin analog, 
GHRP-2, has a protective effect on the liver in rats that seems to be mediated by IGF-I, TNF-alpha, and 
nitric oxide. This anti-inflammatory effect of GHRP-2 in the liver is probably exerted on non-
parenchymal cells [36]. Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats, as a 
result of its anti-inflammatory and anti-oxidant effects [37]. In contrast to saline, ghrelin treatment 
ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats [38]. Taking all 
these data into account, decreased ghrelin levels could be a contributing factor for the deterioration of 
liver function in cirrhosis. It can be speculated that exogenously administered ghrelin may have an effect 
against liver failure, as well as to overcome anorexia and protein wasting of patients with cirrhosis. 
 
The basal concentrations of ghrelin have been reported to be deranged in liver cirrhosis, but the results 
are controversial. Ghrelin levels have been found normal, increased, and decreased in hepatic failure 
patients [4, 31-35]. The response of ghrelin after an OGTT has not been studied in hepatic failure 
patients. 
 
Our aim was to study circulating fasting ghrelin levels and their response to an OGTT in liver failure 
patients prior to liver transplantation and normal control subjects matched for age, sex, and BMI, and 
their relation with glucose and insulin. 
  
Results 
The basic characteristics of the patients and healthy control subjects are shown in Table 1. 
Table 1. Basic characteristics in all subjects (median and range) 
  Patients Controls P 
    
Male/Female 11/5 6/4 Ns 
Age (years) 54 (23–66) 58.5 (54–65) Ns 
BMI (kg/m2) 27.3 (18.6–33.7) 25.4 (20–29.7) Ns 
MELD score 11.5 (2.8–20.5)     
Child-Pugh score 9.1 (5–12)     
Albumin (g/dl) 3 (2.8–3.5) 4.1 (3.4–5.3) 0.001 
Bilirubin (mg/dl) 2.9 (0.5–12.7) 0.5 (0.4–0.9) 0.001 
Etiology 
Alcoholic 7     
Viral 5     
Hepatocellular carcinoma 3     
PBC 1     
    
 
BMI body mass index 
MELD model for end-stage liver disease 
PBC primary biliary cirrhosis 
Ns non significant 
Fasting serum levels 
Fasting glucose and insulin (median and range) were similar in the end-stage liver failure patients and 
in the control group, basal glucose 96 (62–168) mg/dl vs. 95 (89–109) mg/dl, P = Ns; fasting insulin 8.3 
(2.0–27) μU/ml vs. 5.0 (2–12) μU/ml, P = Ns, for patients and controls, respectively. Insulin resistance, as 
estimated by HOMA scores (median and range), was not statistically different between patients and 
controls 2.0 (0.2–9.6) vs. 1.1 (0.4–2.7) P = Ns, although there was a tendency toward higher levels in the 
end-stage liver failure group. Fasting GH (median and range) levels were statistically significantly higher 
in patients than in controls, 2.6 (0.2–6.9) μg/l vs. 0.2 (0.1–0.9) μg/l, P = 0.001, for patients and controls, 
respectively. Fasting IGF-I (median and range) levels were statistically significantly lower in patients 
than in controls, 32 (25–112) ng/ml vs. 87 (52–102) ng/ml, P = 0.008, for patients and controls, 
respectively. Fasting ghrelin (median and range) levels were statistically significantly lower in patients 
than in controls, 527 (377–971) pg/ml vs. 643 (523–2163) pg/ml, P = 0.045, for patients and controls, 
respectively. In Fig. 1 we show fasting serum levels (mean values ± SEM) of ghrelin (pg/ml), GH (μg/l), 
and IGF-I (ng/ml) in liver failure patients and controls. 
  
 
 
 
Fig. 1. Fasting serum levels (mean ± SEM) of ghrelin 
(pg/ml), GH (μg/l), and IGF-I (ng/ml) in liver failure patients 
and controls. * P < 0.01 
Serum levels after oral glucose 
Glucose was higher in the end-stage liver failure group than in the control group after the OGTT. At 
120 min after the OGTT, glucose was higher in liver failure patients than in the control group, 236 (93–
346) mg/dl vs. 95 (57–164) mg/dl, for patients and controls, respectively, P = 0.001. The area under the 
secretory curve (AUC) of glucose were statistically significant higher in patients than in controls, 23955 
(16530–39615) mg/dl min vs. 14775 (12030–20805) mg/dl min, for patients and controls, respectively, 
P = 0.001. Insulin levels were not statistically different between the two groups at any point of the curve. 
The AUC of insulin were not statistically significant different between patients and controls, 5533 (1945–
18318) μU/ml min vs 4107 (2068–12441) μU/ml min, for patients and controls, respectively, P = Ns. 
Figure 2a and b show serum glucose and insulin levels (mean values ± SEM) in end-stage liver failure 
group and normal subjects during the OGTT. 
 
 
  
 
 
 
Fig. 2. a Mean ± SEM plasma glucose (mg/dl), in liver failure patients and controls 
during the oral glucose tolerance test. *P < 0.01 between patients and controls at that 
time point. b Mean ± SEM serum insulin levels (μU/ml) in liver failure patients and 
controls during the oral glucose tolerance test 
Ghrelin levels decreased during the OGTT, and nadir ghrelin levels were statistically lower than 
fasting total ghrelin levels for both patients and controls; patients: 527 (377–971) pg/ml vs. 441 (318–
626) pg/ml, for fasting and nadir ghrelin, respectively, P = 0.001; controls: 643 (523–2163) pg/ml vs. 567 
(442–1154) pg/ml, for fasting and nadir ghrelin, respectively, P = 0.008. 
 
Ghrelin was lower in the end-stage liver failure group than in the control group after the OGTT. Nadir 
ghrelin levels were lower in end-stage liver failure patients than the control group, 441 (318–626) pg/ml 
vs. 567 (442–1154) pg/ml, for patients and controls, respectively, P = 0.02. The median (range) reduction 
in total ghrelin levels during the OGTT was not different between the two groups, 100 (26–448) pg/ml vs. 
150 (0–1009) pg/ml for patients and controls, respectively; P = Ns). The AUCs of total ghrelin were 
lower in end-stage liver failure patients than in the control group, 58815 (44730–87420) pg/ml min vs. 
76560 (56160–206385) pg/ml min, for patients and controls, respectively, P = 0.027. Figure 3 shows 
serum ghrelin levels (mean values ± SEM) in end-stage liver failure patients and normal subjects during 
the OGTT. In Table 2 we show fasting and post-OGTT biochemical and hormonal data (median and 
range) in patients and controls. 
  
 
 
 
Fig. 3. Mean ± SEM serum ghrelin levels (pg/ml) in liver failure patients and controls 
during the oral glucose tolerance test. *P < 0.05 between patients and controls at that 
time point 
Table 2. Fasting and after an OGTT biochemical and hormonal data (median and range) in patients and controls 
 
Patients Controls P 
    
Fasting glucose 96 (62–168) 95 (89–109) Ns 
Glucose after OGTT 236 (93–346) 95 (57–164) 0.001 
Fasting insulin (μUI/ml) 8.3 (1.0–26.7) 5.1 (2.0–12.0) Ns 
HOMA 2.0 (0.2–9.6) 1.1 (0.4–2.7) Ns 
GH (μg/l) 2.6 (0.2–6.9) 0.2 (0.1–0.9) 0.001 
IGF-I (ng/ml) 32 (25–112) 87 (52–102) 0.008 
Fasting ghrelin (pg/ml) 527 (377–971) 643 (523–2163) 0.045 
Nadir ghrelin (pg/ml) 441 (318–626) 567 (442–1154) 0.02 
AUC ghrelin (pg/ml min) 58815 (44730–87420) 76560 (56160–206385) 0.027 
    
 
HOMA homeostasis model assessment 
AUC area under the secretory curve 
Glucose after OGTT 120 min glucose after oral glucose tolerance test 
Ns non significant 
Correlations 
Although the number of patients for the correlation studies was small, we analyzed if there was 
significant correlation between fasting ghrelin levels and age, BMI, IGF-I, fasting glucose, glucose at any 
point during the OGTT, basal GH, fasting insulin, insulin at any point during the OGTT, insulin 
resistance as estimated by HOMA, glucose peak, insulin peak, glucose AUC, and insulin AUC. In the 
group of liver failure patients, fasting total ghrelin levels negatively correlated with basal GH (r = −0.626; 
P = 0.02) (Fig. 4). We were unable to discover any other significant correlation. 
  
 
 
 
Fig. 4. Fasting total ghrelin (pg/ml) and fasting GH (μg/l) levels 
correlation in liver failure patients (r = −0.626; P = 0.02) 
We studied the correlation between the degree of reduction of total ghrelin levels during the OGTT 
and age, BMI, IGF-I, fasting glucose, glucose at any point during the OGTT, basal GH, fasting insulin, 
insulin at any point during the OGTT, insulin resistance as estimated by HOMA, fasting total ghrelin 
levels, glucose peak, insulin peak, glucose AUC, and insulin AUC. In the group of liver failure patients, 
the degree of reduction in ghrelin levels negatively correlated with BMI (r = −0.556; P = 0.03) (Fig. 5). 
With regard to this correlation, if we exclude the patient with the greatest reduction in ghrelin there is still 
an important correlation (r = −0.482), although the results are borderline non-significant (P = 0.069). We 
believe that the loss of significance is due to our relatively small number of patients, although that there is 
no reason to exclude the data for this patient, as it is similar in clinical and analytical terms to the general 
patient group. We were unable to discover any other significant correlation. 
 
 
 
Fig. 5. Degree of reduction in ghrelin (pg/ml) levels after an oral 
glucose tolerance test (OGTT) and body mass index (BMI) correlation 
in liver failure patients (r = −0.556; P = 0.03) 
 
  
Discussion 
We have found significantly decreased plasma levels of ghrelin both fasting and post-OGTT in end-
stage liver failure patients candidates for transplantation when compared with control subjects. 
Furthermore, ghrelin levels were similarly suppressed after glucose ingestion in patients with liver failure 
candidates for transplantation. 
 
During its synthesis, ghrelin is acylated on serine-3 with an esther-linked fatty acid group [39, 40]. 
This acylation is essential for the activity of ghrelin at the GH secretagogue receptor [10, 41] and 
probably for its orexigenic actions. However, des-acyl ghrelin has multiple biologic activities [42, 43, 44, 
45, 46, 47]. One limitation of our study is that we did not measure acyl ghrelin, although there are 
concerns about the especificity of available acyl-ghrelin assays [30]. In the classic studies, total ghrelin 
levels increase preprandially and drop rapidly after meals, suggesting that total ghrelin plays a role in 
short-term regulation of food intake [28, 48]. Recent data from Thorner′s group have shown, in men, that 
under postprandial conditions ghrelin and des-acyl ghrelin levels changed in parallel, with sharp declines 
after feeding both during normal and experimental feeding [49]. In contrast, under fasting conditions the 
balance of ghrelin to des-acyl ghrelin was altered, with acyl-ghrelin levels near the nadirs observed on the 
fed day [50]. This data could raise some concerns about the orexigenic properties of acyl-ghrelin under 
fasting conditions, and confirm that under postprandial conditions total ghelin and acyl-ghrelin change in 
parallel. The total ghrelin data from the current study allow us to compare these results with the 
discrepant total ghrelin levels that have been found in hepatic failure patients in different studies [4, 31, 
32, 33, 34, 35]. 
 
Fasting total ghrelin levels have been studied in hepatic failure patients, with increased ghrelin levels 
found in some studies [32, 35]. Atavesen et al. [32] found that in cirrhosis serum ghrelin levels were 
increased with a corresponding decrease in serum leptin concentrations. The increase of ghrelin was more 
prominent in Child C cirrhosis and the level was correlated with TNF-alpha. Tacke et al. [35] found that 
ghrelin was significantly elevated and IGF-1 reduced in chronic liver disease patients compared with 
healthy controls. IGF-1 serum levels inversely correlated with Child’s classification. Ghrelin levels were 
significantly elevated in Child C cirrhosis patients regardless of the etiology of liver disease. Ghrelin 
levels did not correlate with liver function. Normal ghrelin levels have been found in other studies [4, 31, 
33]. Kalaitzakis et al. [31] found that patients with cirrhosis had similar fasting ghrelin levels to a control 
group. In contrast, patients with cirrhosis had higher postprandial glucose and lower ghrelin 
concentrations at 4 h postprandially than the control subjects. In the study by Takahashi et al. [33], 
plasma ghrelin levels were slightly but not significantly elevated in patients with liver cirrhosis when 
compared with controls. Plasma ghrelin levels were significantly correlated with BMI, but not with the 
severity of liver damage. In the study by Marchesini et al. [4], ghrelin levels were not increased in 
cirrhosis but increased with decreasing Corli score, a method used to quantitate and score the amount of 
ingested food, and along the scale of anorexia/hunger. Similarly to our results, although in patients with 
primary biliary cirrhosis, Breidert et al. [34] found that serum ghrelin levels were decreased compared to 
the control group. In the current study, we found decreased fasting and post-OGTT ghrelin in patients 
with cirrhosis candidates for transplantation. 
 
Discrepancies between the different studies, including our own, could at least be partly explained by 
different patient selection, control subject selection, or both. The different causes of cirrhosis with a wide 
range of insulin sensitivity could have an impact on total ghrelin levels. Some of the patients in the 
different studies had a wide range of hepatocellular dysfunction and were not BMI-matched with control 
subjects. In the current study, all patients were liver failure patients candidates for transplantation and 
BMI-matched control subjects were chosen. However, due to the hepatocellular dysfunction and the 
heterogeneous nature of liver failure patients, our study patients were not perfectly matched with the 
control group, for example GH, IGF-I, and postprandial glucose were all different. In nonalcoholic fatty 
liver disease, ghrelin levels have been found decreased and correlated with insulin resistance [51]; in 
contrast with those patients with normal liver function, in the current study the severity of liver damage 
was advanced. Nevertheless, both studies suggest that in liver disease ghrelin levels are decreased, 
although probably through different mechanisms. 
 
To our knowledge, only one study exists of postprandial ghrelin levels in liver cirrhosis. Similarly to 
our results, the patients with cirrhosis had lower ghrelin concentrations at 4 h postprandially than the 
control subjects, although fasting ghrelin levels were similar to the control subjects [31]. In normal 
subjects there is a decrease in ghrelin levels after the OGTT [27]. The response of post-OGTT ghrelin 
levels in hepatic failure patients was similar to the control group, in both groups ghrelin levels decreased 
during the OGTT, and nadir ghrelin levels were statistically lower than fasting total ghrelin levels for both 
patients and controls. 
 
The mechanisms of altered fasting or postprandial ghrelin response might involve glucose, insulin, 
GH, or all three. Insulinemia is essential for postprandial ghrelin suppression with glucose having an 
additional effect [52, 53, 54]. Therefore, insulin resistance resulting in high postprandial glucose and 
insulin might be involved in the low ghrelin observed post-OGTT. A clearly negative association between 
ghrelin and insulin secretion has been found in humans, as well as in animals by the majority of authors 
[20, 28, 54], although not by all [55, 56]. Ghrelin is a potent stimulus for GH secretion [13, 29] and, at 
least under certain physiologic conditions, ghrelin modulates the regulation of GH secretion [57], 
although the relationship between ghrelin and GH secretion is controversial. In acromegaly, a 
pathophysiological model of increased GH secretion, some studies have found normal ghrelin levels [58, 
59, 60, 61], while others have found decreased ghrelin levels in patients with acromegaly [62, 63, 64], 
suggesting that increased GH could contribute towards the decreased ghrelin levels in a classic feedback 
manner. This said, the number of patients used in the correlation studies was small, and the results should 
be taken with caution. In the current study, fasting total ghrelin levels negatively correlated with basal GH 
in patients with liver failure, suggesting that increased GH could contribute to the decreased fasting 
ghrelin levels. In line with other studies [65], this data supports the hypothesis that GH feedback inhibits 
ghrelin secretion. In liver failure patients, we found decreased IGF-I and increased GH. IGF-I is the main 
circulating inhibitory factor for GH secretion [61, 62, 63]. However, we could not find a significant 
correlation between ghrelin and IGF-I. An alternative explanation for the association between ghrelin and 
GH, could be that it is indirectly due to a relationship between ghrelin and IGF-I. In the current study, the 
degree of reduction in ghrelin levels negatively correlated with BMI in patients with liver failure, in 
accordance with the important influence of nutritional status on ghrelin regulation [19, 20, 21, 22, 23, 27, 
66]. Although a small patient sample was used in this study, we could not find significant correlation 
between fasting ghrelin and the degree of ghrelin suppression after oral glucose on the one hand and 
insulin, glucose or IGF-I levels on the other, suggesting that other factors are responsible for fasting 
ghrelin and the decrease in ghrelin in liver failure patients who are candidates for transplantation. Further 
studies are needed to clarify the mechanisms responsible for the decrease of ghrelin after oral glucose in 
liver failure patients. 
 
Ghrelin is the only established circulating orexigenic hormone. Ghrelin enhances appetite and food 
intake, and its concentration rises preprandially, thereby playing a role in meal initiation. The infusion of 
ghrelin led to short-term increases in hunger in human subjects [17]. Concentrations of fasting ghrelin are 
increased in anorexia and cachexia but reduced in obesity [19, 20, 21, 22, 23], probably due to a 
compensatory mechanism. Disordered circulating ghrelin levels could participate in the altered nutritional 
status of different clinical situations such as chronic renal failure [67, 68, 69]. The presence of decreased 
ghrelin levels both fasting and post-OGTT could contribute to the anorexia of patients with advanced 
liver failure. 
 
In conclusion, we found significantly decreased plasma levels of ghrelin both fasting and post-OGTT 
between patients with liver failure who were candidates for transplantation and control subjects. 
Furthermore, ghrelin levels were similarly suppressed after glucose ingestion in patients with liver failure 
who were candidates for transplantation. These data suggest that decreased ghrelin levels could contribute 
to the anorexia of patients with advanced cirrhosis. 
  
Patients and methods 
Patients 
We included 16 patients (11 male, 5 female) with liver failure prior to liver transplantation, median 
(range) age of 54 (23–66) years, median (range) body mass index (BMI) of 27.3 (18.6–33.7) kg/m2. As a 
control group 10 age and BMI matched healthy or overweight subjects (6 male, 4 female), selected from a 
pool of volunteers available to our unit, were included, median (range) age of 58.5 (54–65) years, median 
(range) BMI of 25.4 (20–29.7) kg/m2. 
 
The diagnosis of liver cirrhosis was established histologically; on the basis of its clinical, laboratory, 
endoscopic, or imaging features; or both. The severity of liver disease was assessed according to Child-
Pugh and the Model of End Stage Liver Disease scores. The causes of the liver cirrhosis were as follows: 
in 7 patients alcohol was the primary cause of the disease; in 5 patients, the cause was viral hepatitis 
(hepatitis B in 1 case; hepatitis C in 4 cases); in 3 patients the cause was hepatocellular carcinoma; in 1 
patient the cause was primary biliary cirrhosis. At the time of the study, the patients with alcoholic liver 
disease had been abstaining from alcohol for 6 months or more. All cases had routine biochemical 
investigation, an ultrasound scanning of the liver, and a gastrointestinal endoscopy. Among the liver 
failure prior to liver transplantation patients there were 3 diagnosed of diabetes mellitus prior to the study 
protocol and were being treated with dietetic therapy. All patients had a markedly suppressed appetite. All 
patients were ambulatory. 
Study procedure 
Between 08.30 and 09.00 a.m., after an overnight fast and while seated, a peripheral venous line was 
obtained. Fifteen minutes later 75 g of oral glucose were administered. We obtained blood samples for 
glucose, insulin, and ghrelin at baseline (fasting) and then at 30, 60, 90, and 120 minutes, respectively. 
Basal levels of GH and IGF-I were also measured. All blood samples were immediately centrifuged, 
separated, and frozen at −80°C. Samples destined to be used for the determination of plasma ghrelin were 
specifically retrieved in chilled tubes containing aprotinin and EDTA-Na, and then immediately 
centrifuged at 4°C., separated to aliquots and frozen at −80°C. The study protocol fulfilled the 
requirements of the ethical committee of our center and written informed consent was obtained from all 
patients and controls. 
Assays 
Plasma glucose (mg/dl) was measured with an automatic glucose oxidase method (Roche Diagnostics, 
Mannheim, Germany). Insulin (μU/ml) was measured with a solid-phase two-site chemiluminescent 
immunometric assay (Immulite 2000 Insulin, DPC, Los Angeles, CA, USA) and with intrassay 
coefficients of variation of 5.5%, 3.3%, and 3.7% for low, medium, and high plasma insulin levels, 
respectively. Serum GH (μg/l) was measured by a solid-phase, two-site chemiluminescent enzyme 
immunometric assay (Immulite, EURO/DPC) with a sensitivity of 0.01 μg/l and with intrassay 
coefficients of variation of 5.3%, 6.0%, and 6.5% for low, medium, and high plasma GH levels, 
respectively. IGF-I (ng/ml) was determined by a chemiluminescence assay (Nichols Institute, San 
Clemente, CA, USA) and with intrassay coefficients of variation of 4.8%, 5.2%, and 4.4% for low, 
medium, and high plasma IGF-I levels, respectively. Total ghrelin (pg/ml) was measured by a 
commercially available radioimmunoassay (RIA) (Linco Research Inc., St Charles, MO, USA), specific 
for total ghrelin, that uses 
125
I-labeled ghrelin tracer and rabbit antighrelin serum with a specificity of 
100%, and with intrassay coefficient of variation between 4.4% and 10%. 
 
All samples from a given subject were analysed in the same assay run. AUC was calculated by a 
trapezoidal method. Insulin resistance was calculated on the basis of fasting values of plasma glucose and 
insulin, according to the homeostasis model assessment (HOMA-IR) method [70] as follows: HOMA-
IR = fasting insulin levels × fasting glucose levels/22.5, where basal insulin levels is in μU/ml, and 
glucose is in mmol/l. 
  
Statistical analysis 
The results are presented as median (range). All comparisons were based on univariate, nonparametric 
tests. Intragroup comparisons were based on Wilcoxon sign-rank test. Comparisons between patients and 
controls were based on Mann–Whitney U test. Numerical correlations were analyzed using the 
Spearman’s correlation test. P values ≤0.05 were considered to be significant. For graphic presentation 
we use mean values ± SEM. The SPSS software 12.0 (Chicago, IL, USA) was used to produce statistical 
analysis. 
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